Collplant Biotechnologies Ltd. · NASDAQ:CLGN
Collplant Biotechnologies — CollPlant Holdings — Investor Presentation (May 2019)
29 slides from Collplant Biotechnologies's investor presentation, May 1, 2019
Slide 1: CollPlant Company Presentation
ff CollPlant XS Revolutionizing Tissue Repair = Company Presentation Yehiel Tal, CEO May 2019
Slide 2: Safe Harbor Statement
Safe Harbor Statement Certain statements in this presentation constitute "forward-ookirg statements" within the mearing of Section 27A of the Securities Act and Section 21€ of the Securities Exchange Act and are usually identified by the use of words such as “anticipates,” “believes,” “estimates,” “
Slide 3: Overview
Overview e Regenerative medicine company developing and commercializing products for tissue repair and organs manufacturing @ Proprietary technology enables the cost- efficient production of high-quality recombinant human collagen (rhCollagen) @ Products initially aimed at 3D Bioprinting, medical ae
Slide 4: Experienced management team
<n Prof. Oded Shoseyov Co-Founder & Chief Scientist Pauli Clean Tech CBD Tech. Fulcrum-SPD Melodea Hebrew University Nadav Orr, PhD VP R&D Ethicon Biosurgery, Johnson & Johnson Experienced management team din Yehiel Tal CEO Regentis Biomaterials ProChon Biotech Kulicke & Soffa Industries ~ Ilana Bel
Slide 5: CollPlant's technology
CollPlant’s technology Co-expression of 5 human genes in tobacco plants for the production of functional type | human recombinant Collagen Tobacco plant Tobacco plant Stable production Structural géfies Enzyme CMe in tobacco plant P4Ha ee re wae LH-3 Post translational modifications e QfcollPiant sn
Slide 6: Cost effective and scalable production
CollPlant’s technology: Cost effective and scalable production Plant Leaves Protein Concentrate Collagen PLANTLETS Q) ¥ (>) PURIFICATION S END PRODUCT IN NURSERY CROW ING EXTRACTION & FILLING FABRICATION ——_— eo ( PcollPiant WL pcisnteg sae Rep
Slide 7: Plant-derived rhCollagen
Plant-derived rhCollagen Clear advantages over animal-derived collagen al | * Accelerates human cell proliferation Faster tissue healing * Controlled physical/rheological properties * Reproducibility ¢ Transparency (not visible) * Non-immunogenic * Non-allergenic *No pathogens *No foreign body respo
Slide 8: Business overview
Business overview 3D Aesthetic bioprinting* medicine * Organs * Co-development *In house 1st GEN dermal filler * Scaffolds & *In house 2nd GEN dermal filler SF conf * Tissues * EU distribution via Arthrex * EU distribution * Developing ROW * Post Marketing Surveillance distribution Orthobiologics Ad
Slide 9: Medical aesthetics
Medical aesthetics Regenerative dermal filler CollPlant Revolutionizing Tissue Repalr
Slide 10: Dermal Fillers
Dermal Fillers 2017 Procedure breakdown, U.S (by material)* ~2,091,476 HA procedures in ho Me as 2017 in the US* 3% Global dermal filler market, 2016** | Calcium Hydroxylapatite Collagen a, . @Fat Cost per syringe: ~ Hyaluronic acid $100-$250/unit*** mPolylactic acid mPolymethyl methacrylate microsp
Slide 11: Combining the advantages of Collagen and Hyaluronic Acid
Combining the advantages of Collagen and Hyaluronic Acid Physical properties * Highly viscous: Provides mechanical stability after injection best of both * Convenient injection: re 37-32G needle, 10-15N expression force rhCollagen Biological properties * Promotes cell adhesion and jj proliferation 1
Slide 12: Photocurable rhCollagen-HA dermal filler for facial aesthetics
24 Gen dermal filler: Photocurable rhCollagen-HA for facial aesthetics Injectable Photo-curable methacrylate-rhCollagen for in-situ photocuring Injection Sculpturing Photocuring in-situ ~~ ¢rhCallagen \ inside (stabilization) (12) CollPlant ong Te Rep
Slide 13: 3D Bioprinting
3D Bioprinting organs, tissues & scaffolds ;CollPlant t lonlzing Tissue
Slide 14: Average transplant costs and wait times in USA
Average transplant costs and wait times in USA: HEART (2,725/YEAR) $1.4 million 191 days LUNGS (1,397/YEAR) $1.2 million 185 days LIVER (6,158/YEAR) $813,000 239 days KIDNEY (16,804/YEAR) $415,000 679 days PANCREAS (136/YEAR) $347,000 281 days CORNEA (50,099/YEAR) $30,200 50 days The advent of 3D bi
Slide 15: Bioink for 3D printing of tissues and organs
a . Biolnk for 3D printing of rhCollag pe tissues and organs CollPlant’s rhCollagen-based Biolnk offers ideal characteristics for 3D bioprinting Optimal rheology at room Biocompatible — temperature - Viscosity and supports viability of gelation kinetics different cell types DOMIMMURCE ERIC) — Tunabl
Slide 16: rhCollagen Bioink
rhCollagen Biolnk Compositions in development (with partners/collaborators) Direct Ink Writing (DIW) Additives (Synthetic/Natural) Cells ———° fc » | Gcoutplant —_—_»9 Bioink y oo 20mI Chemical modifications Projection Stereolithography Laser Induced Forward Growth Factors ————® oO Transfer (LIFT) (i
Slide 17: Bioink business segments and focus areas
Biolnk business segments and focus areas i | Endocrine glands Tissues Scaffolds * Ovary Skin Spine fusion ¢ Pancreas Cornea Non-union fractures * Thyroid Bones Craniomaxillofacial Cartilage Nerve conduits Blood vessels Tendons & ligaments Heart valves ORGANS OVARY SPINE FUSION EXTREMITIES Collaborat
Slide 18: Collaboration agreement with United Therapeutics
Collaboration agreement with United Therapeutics (Oct. 2018) ° Global licensing and commercialization Agreement highlights: agreement for 3D Bioprinting of solid organ * $5M upfront payment scaffolds for human transplants ° Up to $39M milestone and option payments : , D . * Royalties on product sale
Slide 19: 3D bioprinting of trachea and bronchi
3D bioprinting of trachea and bronchi Organ ] Manufacturing) Grour 1001p perfused vessels ® Courtesy of United Therapeutics ( CollPlant Frevcuteting Tse Rep
Slide 20: Commercial products in EU
Commercial products in EU Advanced Wound Care, Orthobiologics UJ Vergen)x-sr EE Dp abet Vergentx-rs Lx | CollPlant Revolutionizing Tssue Repair
Slide 21: VergenixSTR Orthobiologics Soft Tissue Repair
U Ve rg en)x"STR Ortho bi ologics Orthopedic clinics, Current Global Tendonitis Soft Tissue Repair US*: served market: PRP collection tube from any commercial PRP Kit Platelet-Rich Plasma \ Uy Red Blood cells 16.4M 0.5BS : individuals seeking (mostly steroids) intervention for tendon and ligament in
Slide 22: VergenixSTR at a glance
VergenixSTR at a glance 2017 20 >1,000 Launched by ArthrexSo. Countries Treated patients Significant clinical outcomes Clinical success* Pain reduction** Functionality score** 86% 95% X2 * recovery in pain and motion. Source: Uri Farkash et al, J Shoulder Elbow Surg (2018) @ * knee tendon, Source fo
Slide 23: VergenixSTR Clinical outcomes
é e e Vergen)x"sTR Clinical outcomes Significant advantages over standard of care * > 74% of patients show clinical success at 3M 5 a 86% of patients show clinical success at 6M 4 + 40 patients, single arm, single treatment, 3 & 6 month f/u & + End points — Safety; recovery in pain and motion as mea
Slide 24: VergenixFG
VergenixFG ¢ rhCollagen wound filler intended for management of acute and chronic wounds * CE marked (EU approval) and commercialization commenced by local distributors in EU Made from truly \ 3D scaffold Single ¢ Wounds heal a 3D —_ human collagen \" for deep/ application faster irregular wound sha
Slide 25: VergenixFG Clinical outcomes
Vergen)xFc Clinical outcomes 72% clinically significant wound closure* after 4 months 69% 72% 58% Month 1 Month 2 Month 3 Month 4 =75**) wound closure (%) (N Patients with clinically significant* DayO 12 weeks By month 3: Vergenix™FG: wound closure in 69% of patients Standard of care: wound closure
Slide 26: CollPlant at a glance
Wy (fcollPlant Revolutionizing Tissue Repair NASDAQ (CLGN) listed ADR since Jan. 2018 Market Cap of ~ S20M 40 employees ¢ Strong R&D team ¢ Fully integrated ¢ Production team with seven years track record
Slide 27: Planned upcoming milestones
Planned upcoming milestones e Aesthetics — Dermal Filler - Sign collaboration agreement with strategic partner - Photocurable filler - Complete PoC study Oo e Biolnk - Expand collaborations with Tier 1 companies e VergenixSTR - Expand distribution network outside EU e@ VergenixFG - Expand worldwide
Slide 28: CollPlant investment highlights
CollPlant investment highlights Only commercially viable technology currently available that can produce truly human collagen Multi-billion dollar market: innovative rhCollagen products initially aimed at 3D bioprinting, medical aesthetics, orthopedics and wound care Commercialization of three produ
Slide 29: Thank you
Thank you
CollPlant Holdings — Investor Presentation (May 2019) on 6ix